10th Indian Delegation to Dubai, Gitex & Expand North Star – World’s Largest Startup Investor Connect
HealthTech

PharmEasy Biggest Underperformer In Prosus’ India Portfolio In H1 FY24


SUMMARY

PharmEasy had an IRR of -41% in H1 FY24, as per data released by Prosus in its half yearly financial statements

PharmEasy was the second-biggest underperformer in Prosus’ global portfolio, with only Skillsoft reporting a worse IRR in H1 FY24

Edtech decacorn BYJU’S was another big underperformer for Prosus with an IRR of -24% in H1 FY24

Online pharmacy major PharmEasy was the biggest underperformer in the Indian portfolio of investment giant Prosus during the first half (H1) of the financial year 2023-24 (FY24).

According to Prosus’ financial statements, PharmEasy had an internal rate of return (IRR) of -41% in H1 FY24. In fact, the online pharmacy major was the second-biggest underperformer in Prosus’ global portfolio, with only Skillsoft reporting a worse IRR during the period under review.

A shareholder presentation shared by Prosus revealed that it held a 13% stake in PharmEasy at the end of September 2023. It also showed that the investment giant increased its stake in the online pharmacy unicorn during the period under review. 

However, Prosus marked down PharmEasy’s valuation amid the startup’s financial troubles. 

“Another is a write down in PharmEasy of about $118 Mn and that’s really driven by the need for PharmEasy to raise money to settle debt. We actually participated in that round which expresses our confidence in the business going forward,” a Prosus spokesperson said.

The startup recently raised INR 3,500 Cr (around $424 Mn) in a rights issue, in which Prosus also participated. The rights issue was oversubscribed, according to PharmEasy cofounder Dhaval Shah.

PharmEasy was looking to settle a portion of its debt from the proceeds of the rights issue.

Beyond PharmEasy, edtech decacorn BYJU’S was another big underperformer for Prosus, having reported an IRR of -24% during the six month period ended September 2023.

Meanwhile, Prosus earned profitable returns from other Indian firms in its portfolio, including Swiggy, Eruditus, PayU India, Meesho and Elastic Run. Prosus reported a profitable IRR of 7% for Swiggy, and 22% for Eruditus. It also earned 30% positive returns from PayU India, 32% from Meesho, and 31% from Elastic Run in H1 FY24.

Overall, the investment major’s operating loss rose to $415 Mn in H1 FY24 from $329 Mn in the year-ago quarter. The company attributed the surge in loss to an impairment loss recognised with respect to edtech investments.

Earlier today, Prosus also slashed BYJU’S valuation down to under $3 Bn, more than 85% lower than the edtech giant’s peak valuation of $22 Bn it commanded during its last funding round.





Source link

by PNN

Bengaluru (Karnataka) [India], November 8: Healthy Hubba, India’s first Children’s Health Festival & Childhood Obesity Conference, will be held on Saturday, November 15, 2025 at the Indian Institute of Science (IISc), Bengaluru. The event is co-presented by Solutionec and Hlty Beings, with support from Rotary Bengaluru Platinum City (District 3192) and quiz partner Quizarre. The festival has been planned against the backdrop of growing concern over childhood obesity and lifestyle-related health problems in India. The programme focuses… Source link

by PNN

ACTIZEET: The Himalayan Promise: Purity, Potency, Purpose   Kolkata (West Bengal) [India], November 7: ACTIZEET, India’s trusted name in pure herbal wellness, proudly marks its 29th anniversary this year. Established in 1996, ACTIZEET began as a small Himalayan initiative to bring authentic Shilajit to the world, and today it stands as a legacy brand that has redefined purity, potency, and purpose in the Indian wellness landscape. From a Modest Beginning to a National Legacy What started in the serene Drass Valley of Ladakh under the vision… Source link

by PNN

Mumbai (Maharashtra) [India], November 5: Low premiums look pleasing when comparing health insurance plans, yet the price on the screen can hide expenses that appear only when a claim is made. The real cost often sits in the policy wording and in how efficiently claims are paid. This blog will cover an easy way to read the claim settlement ratio, how “cheap” options can cost more at claim time, and a checklist for sensible comparison. What Claim Settlement Ratio Really Tells You The claim settlement ratio shows the share of claims an… Source link